In the race to hold more assets as the adult-use legalization of cannabis arrives in Canada, Choom (CSE:CHOO; OTCQB:CHOOF) announced on Monday (March 19) that the company will acquire a late stage Access to Cannabis for Medical Purposes Regulations (ACMPR) applicant through an amalgamation deal.

The transaction will take place between Choom’s subsidiary Arbutus Brands and International Tungsten. The actual license, if approved, will come from Specialty Medijuana Products, a company based in Sooke, B.C. which International Tungsten has agreed to acquire.


According to Choom, Specialty Medijuana Products submitted its Affirmation of Readiness evidence package to the country’s regulatory agency in the cannabis industry, Health Canada. Choom added it expects a cultivation license to arrive “within the next several weeks.”

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

Choom also provided an outline of the development the company plans to follow with the current facilities up for inspection by Health Canada. For the next two phases of development, Choom plans to expand the current production capacities to over 29,000 square feet. Then it will construct two new additional buildings for the increase of total production.

“This new facility, a hybrid model of indoor and greenhouse production, is expected to bring Choom’s total production capacity to over 750,000 [square feet,]” Choom revealed.

Details of the transaction for Choom

Holders of International Tungsten common shares will be issued, according to Choom, one common share of the company in exchange for every share of held, up to a combined maximum of 92,000,000 common shares.

“Choom has completed an offering of subscription receipts, at a price of $0.60 per subscription receipt, for aggregate gross proceeds of $7.0 million,” the company said.

Investor takeaway

Choom is a company in the movement of brand recognition leading its pitch to investors. Its products are designed to appeal to the lifestyle aspect of consuming cannabis and, so far, the company has not made a big push into the cannabis for medical purposes business.

Steven Feldman is an active cannabis investor and serves as a co-founder and director of Liberty Leaf Holdings (CSE:LIB), who also manages the popular @CanadaPotStocks Twitter account,told INN some of the newcomers in the public space are starting to downplay the production capacities and focusing on the lifestyle aspect or the brands proposed to display for consumers.

According to the TMX Money tool on Monday, Choom’s share price closed with a day increase of 19.10 percent, equaling a $0.17 gain to reach $1.06.

Don’t forget to follow us @INN_Cannabis  for real-time news updates! 

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less

Recap of special management call includes upcoming corporate milestones and details of proposed combination with established beverage manufacturer

Emerging leader in infused cannabis beverages, BevCanna Enterprises Inc. (CSE:BEV, OTCQB:BVNNF, FSE:7BC) (“BevCanna” or the “Company”) is pleased to provide a recorded recap of the special management call held on Tuesday November 24, 2020. The call discussed upcoming corporate milestones and reviewed recent developments at the developer and manufacturer of cannabinoid‐infused beverages and consumer products for in‐house brands and white label clients.

Keep reading... Show less